Kamran Alam - 31 May 2023 Form 4/A - Amendment Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ Kamran Alam
Issuer symbol: TSHA
Transactions as of: 31 May 2023
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 10 Apr 2025, 16:15:13 UTC
Date Of Original Report: 02 Jun 2023
Previous filing: 06 Feb 2023
Next filing: 25 Aug 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TSHA	Employee Stock Option (right to buy)	Award	$0	+12,462		$0.000000	12,462	31 May 2023	Common Stock	12,462	$1.18	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was awarded on February 2, 2023 by the Compensation Committee (the "Compensation Committee") of the Issuer's Board of Directors as annual incentive compensation for 2022 performance. On May 31, 2023, the Compensation Committee certified the achievement of a certain performance goal. The shares underlying the option covered by this report vested upon certification. This option was inadvertently omitted for the original Form 4.

Content

The option was awarded on February 2, 2023 by the Compensation Committee (the "Compensation Committee") of the Issuer's Board of Directors as annual incentive compensation for 2022 performance. On May 31, 2023, the Compensation Committee certified the achievement of a certain performance goal. The shares underlying the option covered by this report vested upon certification. This option was inadvertently omitted for the original Form 4.